# SynOx Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/synox-therapeutics

- Industry: Biotechnology
- Headquarters: Dublin, Ireland
- Website: www.synoxtherapeutics.com
- Total disclosed funding: $119M
- Latest round: Series B (Oct 30, 2024)
- Investors on record: 6

## About

Founded in 2020 and based in Dublin, Ireland, SynOx Therapeutics Ltd. is developing emactuzumab, a monoclonal antibody targeting CSF-1R, to treat tenosynovial giant cell tumors (TGCT) and other related diseases. SynOx Therapeutics Ltd raised venture funding from investor MaasInvest. As of July 2024, the company is led by CEO Ray Barlow.

SynOx Therapeutics Ltd. is developing emactuzumab, a monoclonal antibody that inhibits the CSF-1R receptor. This receptor is involved in the regulation and recruitment of macrophages, which are implicated in various pathologies, including TGCT.

## Funding rounds

- Series B, Oct 30, 2024 — Gilde Healthcare
- Series B, Apr 22, 2024, $75M — HealthCap, Forbion, Bioqube Ventures
- Series A, Nov 19, 2020, $44M — HealthCap, Gimv, Forbion, Medicxi

## Investors

- HealthCap — Series A, Series B
- Gimv (https://capitalatlas.ai/funds/gimv) — Series A
- Forbion (https://capitalatlas.ai/funds/forbion) — Series A, Series B
- Medicxi (https://capitalatlas.ai/funds/medicxi) — Series A
- Bioqube Ventures (https://capitalatlas.ai/funds/bioqube-ventures) — Series B
- Gilde Healthcare (https://capitalatlas.ai/funds/gilde-healthcare) — Series B